Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-319 in B-cell Malignancies
NCT05512390Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2023
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of ABBV-319 in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Dose-Limiting Toxicities at Day 42, Number of Participants with Adverse Events up to 30 Months and 5 more. Started Apr 2023; status: active, not recruiting.
02
Drugs
ABBV-319
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT05512390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05512390.